Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib + CPT in R/R Non-Hodgkin Lymphoma
NCT07195799Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of linperlisib in follicular lymphoma (FL), peripheral T-cell lymphoma (PTCL), Natural killer T-cell lymphoma (NKTL) and 3 more (6 cohorts), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Best Objective Response Rate. Started Dec 2024; status: recruiting.
02
Drugs
linperlisib
03
Conditions
follicular lymphoma (FL)peripheral T-cell lymphoma (PTCL)Natural killer T-cell lymphoma (NKTL)chronic lymphocytic leukemia (CLL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT07195799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07195799.